Moderna’s 12% Rally Puts Flu Shot Catalyst Back at Center Stage
Moderna stock: MRNA breaks to a 52-week high as FDA flu-vaccine momentum revives the mRNA pipeline trade.
Quick overview
- Moderna's stock surged 11.55% to $61.80, reaching a new 52-week high amid positive investor sentiment and upcoming events.
- The company is gaining traction with its experimental flu vaccine, mFlusiva, following favorable FDA reviews that eased regulatory concerns.
- Despite a significant year-to-date increase of over 100%, Moderna faces challenges with negative earnings and the need for successful product launches to sustain its rally.
- Investors should be cautious as the stock is currently overbought, and future performance hinges on the company's ability to diversify its mRNA platform.
Moderna is back in momentum territory.
Shares of Moderna Inc. (NASDAQ: MRNA) closed at $61.80 on June 17, up 11.55%, extending a five-day rally and pushing the stock to a fresh 52-week high. The move followed stronger investor interest ahead of Moderna’s June 25 investor event and improving sentiment around its experimental flu vaccine, mFlusiva.
The rally is not just about one trading session. TradingView shows MRNA up more than 100% year to date and nearly 140% over one year, even though the stock remains far below its pandemic-era highs.
The market is repricing Moderna as something more than a fading Covid vaccine name. But the reset still depends on execution.
Why Is Moderna Stock Up 12% Today?
FDA staff documents eased fears around mFlusiva after earlier regulatory turbulence. Investor’s Business Daily reported that FDA reviewers found no major deficiencies in Moderna’s application, while the agency’s focus appeared to center on risk-benefit questions across age groups.
That matters because Moderna is trying to secure approval for what could become the first U.S. mRNA-based seasonal flu vaccine. The FDA’s target decision date is August 5, 2026, according to recent reports.
The company is also heading into an investor event on June 25, where it plans to discuss research programs, early development, AI, robotics and broader platform expansion.
Recent developments include:
- Positive FDA staff review momentum for mFlusiva.
- EU marketing authorization for mCOMBRIAX, Moderna’s flu-Covid combination vaccine.
- Plans for three vaccine launches over the next two years, including flu, flu-Covid and norovirus.
- Expected 2026 clinical milestones in oncology and rare disease.
- Ester Banque’s appointment as chief commercial officer.
Moderna’s Fundamentals: Watch $5.5-$6 Billion Cash Reserves
Moderna is still rebuilding after the Covid revenue collapse.
TradingView lists Moderna’s market value at about $22 billion, with fiscal revenue of $1.94 billion, net income of -$2.82 billion, and trailing EPS of -$8.15. The stock has no trailing P/E because earnings remain negative.
First-quarter results showed the same split personality. Revenue rose to $389 million from $108 million a year earlier, driven by international Covid vaccine sales. But Moderna posted a $1.34 billion net loss, including roughly $900 million tied to litigation settlement expenses, according to WSJ coverage.
The balance sheet remains a key support. Moderna has guided for year-end cash reserves of roughly $5.5 billion to $6 billion, while continuing to invest heavily in R&D.
The bull case is straightforward: Moderna has approved products, global manufacturing scale, a large cash cushion and a platform that could expand into flu, combination respiratory vaccines, oncology and rare diseases.
The bear case is also clear: the company is burning cash, Covid demand remains uncertain, and the pipeline must deliver commercial products fast enough to justify the rally.
MRNA Technical Analysis: Can the Moderna Rally Continue?
The chart has turned sharply bullish, but it is stretched.
MRNA closed above every major moving average listed in the daily TradingView data:
- 10-day EMA: $52.29
- 20-day EMA: $50.52
- 50-day EMA: $49.60
- 100-day EMA: $47.27
- 200-day EMA: $43.53
- 200-day SMA: $39.02
That confirms a broad trend reversal. Short-term, medium-term and long-term averages all sit below price. The stock has also cleared the prior 52-week high area around $59.57.
Momentum is strong. MACD is on a buy signal, and the 10-day momentum reading is positive. But the rally is hot. RSI at 72.78 sits in overbought territory, while Stochastic %K at 92.96 and Stochastic RSI at 100 show short-term exhaustion risk.
One caution: ADX is only 15.86. That suggests the breakout is powerful but the underlying trend strength is still developing. In plain English, buyers have control, but the move needs follow-through.
Key Levels to Watch for MRNA Stock
- Immediate resistance: $62-$65
- Next upside zone: $70-$75
- Larger psychological level: $80
- First support: $59-$60, near the breakout zone
- Secondary support: $57.20, near the Hull moving average
- Deeper support: $53.10, near the Ichimoku base line
- Major support: $49-$51, where several moving averages cluster
What’s Next for Moderna Stock in 2026?
Moderna’s long-term story is no longer just about Covid. It is about whether the company can convert its mRNA platform into a diversified product engine.
The opportunity is meaningful. Flu, Covid-flu combination shots, RSV, norovirus, oncology and rare disease programs could expand Moderna’s revenue base. The personalized cancer vaccine program with Merck remains one of the most important longer-term catalysts.
But the valuation now assumes progress. The stock has already more than doubled over the past year. That leaves less room for disappointment if the FDA delays mFlusiva, investor day underwhelms, or late-stage oncology data fail to impress.
For investors, Moderna is a higher-risk recovery trade with real platform upside. For traders, the chart is bullish but overbought. The next test is whether MRNA can hold the breakout after the news-driven buying fades.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
Save